ClinicalTrials.gg
Not yet recruitingNCT05340803Updated Apr 22, 2022

Sedation of Ventilated Traumatic Brain Injury Patients With Midazolam Alone Versus Combination With Dexmedetomidine or Magnesium Sulfate; Monitored by Ultrasonograghic Optic Nerve Sheath Diameter

A Phase 3 interventional study of Ultrasonograghic optic nerve sheath diameter US-ONSD and midazolam in TBI (Traumatic Brain Injury), sponsored by Assiut University. Not yet recruiting. Open to participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2022-04-22.

Sponsored by Assiut University · Phase 3, Interventional, and Supportive care

How we know

From the registry’s dates

  • Primary completion was expected by Jan 2025, 1 year 10 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
108
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies testing dexmedetomidine in Brain Injuries, Traumatic — 5 open to participants now, 5 under way, 2 of them phase 3. Dexmedetomidine · Brain Injuries, Traumatic.

Planned enrollment
2nd of 10
108 · median 76
Started
2022
with 1 other
Phase 3
Only one
of the 10
Registered
3rd of 10
by date
Lead sponsor
2 of 10
Assiut University

Among the 10 studies testing dexmedetomidine in Brain Injuries, Traumatic, this one is the 2nd largest by planned enrollment, is one of 2 that started in 2022, is the only one in phase 3, and was the 3rd registered.

Brain Injuries, Traumatic

1,725 studies on the registry are indexed under Brain Injuries, Traumatic; 450 are open to participants now.

Browse Brain Injuries, Traumatic studies →

Open to participants now

5 of the 10 studies testing dexmedetomidine in Brain Injuries, Traumatic are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

About dexmedetomidine

Dexmedetomidine: first FDA approval 1999 (PRECEDEX), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 287 Brain Injuries, Traumatic studies recruiting now, 126 (44%) set no upper age limit and 119 (41%) stop at 75 or younger; 41 take children under 18; 53 take healthy volunteers.

This study: 18 Years to 45 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing dexmedetomidine in Brain Injuries, Traumatic, or all of them as a file.
02

Study summary

In TBI, there is a strong correlation between increased ICP and bad outcome. So, appropriate monitoring can be the gold standard in management of TBI. ICP can be measured by invasive and noninvasive methds. One of these noninvasive methods is bedside measurement of optic nerve sheath diameter (ONSD) by ocular ultrasonography

Read the detailed description

In the previous few years, agreat evidence has established for efficiency of dexmedetomidine (DEX) in management of TBI. Dexmedetomidine is a highly selective alpha-2 receptor agonist, its major sympatholytic and sedative actions are mediated primarily via reduced transmission in the locus coeruleus which is a part of the reticular activating system. It provides excellent sedation without respiratory depression, ease of arousability, and need not be stopped during weaning the patient from mechanical ventilation or for neurological assessment. It suits as an ideal sedative agent for patients with TBI. DEX has been shown to reduce cerebral ischemia/ reperfusion injury by suppressing inflammation, activating the anti-apoptotic signaling pathways, and inhibiting neuronal autophagy. Animal studies have shown that alpha-2 agonists are neuroprotective in craniocerebral and subarachnoid injuries but this has not been definitively shown in humans . The efficacy of DEX for sedation in intubated ICU patients is well established; however, its use in patients with TBI has not been comprehensively described .

Magnesium has shown great promise as a potential therapeutic agent in TBI during animal experiments . Magnesium is essential for the maintenance of cell membrane integrity, the stabilisation of genetic material and for a number of fundamental enzymatic reactions such as glycolysis, oxidative phosphorylation and protein synthesis, it is also known to act presynaptically to inhibit the release of excitatory amino acids, and be a non-competitive inhibitor of the voltage-gated N-methyl-D-aspartate (NMDA) receptor, an important link in the excitotoxic phase of secondary brain injury. As a consequence, magnesium's role in TBI has been of great interest to researchers.

03

Conditions studied

  • TBI (Traumatic Brain Injury)
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Middle age patients ( 18- 45 years old).
  2. Sever TBI (GCS \< 8 and in need for mechanical ventilation).
  3. Stable hemodynamics

Exclusion criteria

Exclusion Criteria:

  1. Age: younger than 18 or older than 45 years old.
  2. Mild and moderate TBI (GCS > 8).
  3. Shocked and hypoxic patients.
  4. to dexmedetomidine as sever hypotension (mean arterial blood pressure \< 60 mmHg), sever bradycardia (heart rate \< 45 beat/min), and AV block in the group that will be sedated by midazolam and dexmedetomidine (group B).
  5. Adverse effects of dexmedetomidine in group B and need to stop it as sever hypotension (mean arterial blood pressure \< 60 mmHg) , sever bradycardia (heart rate \< 45 beat/min), and atrial fibrillation.
  6. Contraindications to magnesium sulfate as heart block, myocardial damage, hypermagnesemia and renal failure in the group that will be sedated by midazolam and magnesium sulfate (group C).
  7. Manifestations of magensium toxicity in group C and need to stop infusion if urine output \< 80 mL in 4 hours, deep tendon reflexes are absent or serum magnesium level > 3.5 mmol/L .
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
108 participants (estimated)

Study arms

  • Active comparator
    Group A

    Sedation by midazolam alone

    Radiation: Ultrasonograghic optic nerve sheath diameter US-ONSD · Drug: midazolam

  • Active comparator
    Group B

    Sedation by midazolam and dexmedetomidine during the first 24 hours

    Radiation: Ultrasonograghic optic nerve sheath diameter US-ONSD · Drug: midazolam · Drug: dexmedetomidine

  • Active comparator
    Group C

    Sedation by midazolam and magnesium sulfate during the first 24 hours

    Radiation: Ultrasonograghic optic nerve sheath diameter US-ONSD · Drug: midazolam · Drug: magnesium sulfate

Interventions

  • RadiationUltrasonograghic optic nerve sheath diameter US-ONSD

    To compare effect of sedation in 3 groups by follow up of intracranial pressure by US-ONSD

  • midazolam

  • dexmedetomidine

  • magnesium sulfate

06

What researchers measure

Primary outcomes

  1. Optic nerve sheath diameter (ONSD) changes by using ultrasound

    ONSD is an indicator for changes in intracranial pressure in response to sedation with midazolam alone versus combination with dexmedetomidine or magnesium sulfate which group will show better control of the increased intracranial pressure to prevent secondary brain insults. ONSD of 5.8mm was used as cutoff point for identifying ICP above 20 mmHg.

    Time frame: up to 24 hours

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2022; primary completion for Jan 2025, 26 months later.

Of 30 phase 3 interventional studies under Brain Injuries, Traumatic, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 69. This study's planned 26 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 17, 2022
First posted
Apr 22, 2022
StartEst.
Nov 1, 2022
Primary completionEst.
Jan 1, 2025
CompletionEst.
Dec 1, 2025
Last update
Apr 22, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 22, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05340803
Lead sponsor
Assiut University
Responsible party
Alshymaa Hassan Mohammed (Doctor, Assiut University) — Principal investigator
First posted
Apr 22, 2022
Start date
Nov 1, 2022 (estimated)
Primary completion
Jan 1, 2025 (estimated)
Completion
Dec 1, 2025 (estimated)
Last update
Apr 22, 2022

Study contacts

Alshymaa Hassan Mohammed, Master
Contact
Alshimaa.hassan@medicine.luxor.edu.eg
01067555351 ext. 01154278436

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Dexmedetomidine · Magnesium Sulfate

Start the discussion